A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation

Phase 2TerminatedNCT05049850

Hansa Biopharma AB3 enrolled

Overview

The purpose of this study is to assess whether imlifidase in combination with bortezomib, belatacept, rituximab and IVIg can suppress donor specific antibodies (DSA) and the occurrence of antibody-mediated rejection (AMR) in highly sensitized patients with chronic kidney disease with a positive crossmatch towards their living donor during a period of 3 months from transplantation.

Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG. Clinical studies with imlifidase have demonstrated that the treatment enables transplantation in patients otherwise highly unlikely to be transplanted, by converting a positive crossmatch to a negative. However, as with other desensitization methods, DSA tend to reappear within weeks after treatment and transplantation, which may cause AMR and increased risk of graft loss. In this study, treatment with imlifidase in combination with approved drugs that prevent or suppress DSA rebound by targeting antibody-producing plasma-cells and their B-cell precursors is suggested. These drugs include (i) bortezomib, a proteasome inhibitor which has activity against mature plasma cells, the source of DSA, (ii) belatacept, a fusion protein which is crucial in blocking T-cell co-stimulation and which is effective in reducing de novo DSA generation in humans, (iii) rituximab, an anti-CD20 monoclonal antibody that targets B-cells and which is an immunomodulatory agent, and (iv) intravenous immunoglobulin (IVIg) which is commonly used in desensitization regimens and for the treatment of AMR. After being informed about the study and potential risks, all patients giving written informed consent will undergo a 2-week screening period to determine eligibility for study entry. Patients who meet the eligibility requirements will then start treatment with belatacept and bortezomib about 3 weeks prior to the imlifidase infusion and transplantation. Rituximab will be initiated 8 days after transplantation and IVIg 10 days after transplantation. Induction and maintenance immunosuppression will also be administered. The patients will be hospitalized for approximately 2 weeks following transplantation and after that 9 follow-up visits to the clinic will take place up to 6 months after transplantation.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Kidney Transplantation in Highly Sensitized Patients

Interventions

ImlifidaseDRUG

Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed Informed Consent obtained before any trial-related procedures * Male or female age 18 to 70 years at the time of screening * Highly sensitized patients registered on the UNOS waiting list for kidney transplantation, with either of the following: * cPRA ≥ 99.9% * cPRA ≥ 98% and have been in kidney paired donation or kidney paired exchange programs for at least 1 year * A positive crossmatch towards a living donor * Willingness and ability to comply with the protocol Exclusion Criteria: * Previous treatment with imlifidase * Previous high dose IVIg treatment (2 g/kg) within 28 days prior to imlifidase treatment * Breast-feeding or pregnancy * Women of child-bearing potential not willing or able to practice FDA-approved forms of contraception. Two medically acceptable methods of highly effective contraception must be used for the duration of the study (e.g. oral, transdermal, intravaginal, injectable or implantable contraceptive; intrauterine device; intrauterine hormone-releasing system; vasectomized partner; bilateral tubal occlusion; or double-barrier method). For a woman to be considered postmenopausal this ascertainment must be made according to medical records and clinical history and may be aided by measurement of elevated postmenopausal serum gonadotropin levels (FSH). * ABO blood group incompatible transplantations (A2 and A2B kidneys will not be accepted for B recipients) * Positive serology for HIV * Clinical signs of HBV, HCV, CMV, or EBV infection * EBV seronegative or with unknown EBV serostatus * Positive SARS-CoV-2 tests at any time point from screening to transplantation * Active tuberculosis * Ongoing serious infections as judged by the investigator * Severe other conditions requiring treatment and close monitoring e.g. cardiac failure ≥ grade 4 (New York Heart Association), unstable coronary disease or oxygen dependent respiratory disease * A history of a proven hypercoagulable condition * Present, or history of, thrombotic thrombocytopenic purpura (TTP) or known familial history of TTP * Intake of investigational drugs (other than imlifidase) within 5 half-lives * Contemporaneous participation in a medical device study * Known allergy/sensitivity (except local reactions) to imlifidase or to any drug (or the excipients) specified in the protocol * Known mental incapacity or language barriers precluding adequate understanding of the Informed Consent information and the trial activities * Inability by the judgement of the investigator to participate in the trial for any other reason

Locations (1)

NYU Langone Health Transplant Institute

New York, New York, United States

Outcomes

Primary Outcomes

Proportion of Patients With DSA Rebound

The recurrence of DSA may cause AMR and increased risk of graft loss. Due to the early termination of the trial the primary endpoint was assessed as the incidence of DSA rebound of either immunodominant or total DSA to a mean fluorescence intensity (MFI) level that was ≥50% of the pre-imlifidase value up to 3 months after transplantation (trial day 91).

Time frame: Up to 3 months after transplantation

Secondary Outcomes

Proportion of Patients With Kidney Biopsy Proven AMR

The standardized international Banff classification 2019 for assessment of renal allograft biopsies will be used to assess AMRs reported from the study based on for cause and protocol biopsies.

Time frame: Up to 6 months after transplantation

Proportion of Patient With DSA Rebound

See description to primary outcome measure

Time frame: Up to 6 months after transplantation

Proportion of Patients With Negative FCXM

Imlifidase is highly efficacious in converting a positive crossmatch to a negative

Time frame: Up to 24 hours after imlifidase treatment

Levels of DSA

Analysis of DSAs before and after imlifidase will be done. The mean fluorescence intensity (MFI) will be presented for the individual patients' DSAs.

Time frame: Within 4 hours before imlifidase until Day 181

Levels of Complement Binding (C1q) DSA

Analysis of C1q DSAs before and after imlifidase will be done. The mean fluorescence intensity (MFI) will be presented for the individual patients' C1q DSAs.

Time frame: Within 4 hours before imlifidase until Day 181

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.